Shield Therapeutics (STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with Feraccru®/Accufer®. News that the FDA has approved this drug for a broad indication opens it up to a commercial market worth over $1bn. STX has been in discussions with a number of potential partners, but its hand has been strengthened by the regulatory de-risking of Accufer. I
05 Aug 2019
FDA approval opens door to major US opportunity
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FDA approval opens door to major US opportunity
Shield Therapeutics Plc (STX:LON) | 1.3 0 (-7.0%) | Mkt Cap: 10.4m
- Published:
05 Aug 2019 -
Author:
Martin Hall -
Pages:
8
Shield Therapeutics (STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with Feraccru®/Accufer®. News that the FDA has approved this drug for a broad indication opens it up to a commercial market worth over $1bn. STX has been in discussions with a number of potential partners, but its hand has been strengthened by the regulatory de-risking of Accufer. I